AFMD Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Affimed N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.095 |
| 52 Week High | US$8.95 |
| 52 Week Low | US$0.07 |
| Beta | 2.07 |
| 1 Month Change | -87.05% |
| 3 Month Change | -91.04% |
| 1 Year Change | -98.16% |
| 3 Year Change | -99.70% |
| 5 Year Change | -99.69% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
ASH 2024 Updates Will Validate Clinical Proof Of Concept
Positive clinical results and safety profile of NK cell engagers boost potential revenue and adoption, enhancing net margins and efficacy.Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
Sep 04Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better
Jun 11The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts
Aug 15
Affimed downgraded to hold at Stifel as pipeline lacks development clarity
Oct 10Health Check: How Prudently Does Affimed (NASDAQ:AFMD) Use Debt?
Sep 17Affimed Q2 2022 Earnings Preview
Aug 10Affimed: Preparing For Key Inflection Points
Jun 29Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
Jun 14Affimed Stock: 3 Points For The Bulls
Apr 09Affimed N.V. (NASDAQ:AFMD) Analysts Just Cut Their EPS Forecasts Substantially
Apr 05Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
Dec 14Affimed: Preparing For A Bullish 2022
Oct 12Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
Aug 19Affimed: Current Fall And Future Prospects
Jul 07We Discuss Why Affimed N.V.'s (NASDAQ:AFMD) CEO May Deserve A Higher Pay Packet
Jun 08Need To Know: Analysts Just Made A Substantial Cut To Their Affimed N.V. (NASDAQ:AFMD) Estimates
Apr 20Shareholder Returns
| AFMD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -29.1% | 0.8% | 1.6% |
| 1Y | -98.2% | -13.8% | 11.7% |
Return vs Industry: AFMD underperformed the US Biotechs industry which returned -13.8% over the past year.
Return vs Market: AFMD underperformed the US Market which returned 11.7% over the past year.
Price Volatility
| AFMD volatility | |
|---|---|
| AFMD Average Weekly Movement | 73.3% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: AFMD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AFMD's weekly volatility has increased from 39% to 73% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 76 | Shawn Leland | www.affimed.com |
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.
Affimed N.V. Fundamentals Summary
| AFMD fundamental statistics | |
|---|---|
| Market cap | US$2.98m |
| Earnings (TTM) | -US$78.93m |
| Revenue (TTM) | US$6.36m |
Is AFMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AFMD income statement (TTM) | |
|---|---|
| Revenue | €5.64m |
| Cost of Revenue | €0 |
| Gross Profit | €5.64m |
| Other Expenses | €75.61m |
| Earnings | -€69.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.27 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,241.26% |
| Debt/Equity Ratio | 46.9% |
How did AFMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 00:02 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Affimed N.V. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | BMO Capital Markets Equity Research |
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Bradley Canino | Credit Suisse |